Loading stock data…
MDT
$78.30-1.70 (-2.13%)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Medtronic plc in the Healthcare sector is trading at $78.30. The stock is currently near its 52-week low of $78.29, remaining 15.7% below its 200-day moving average. Technical signals show oversold RSI of 22 and bearish MACD signal, explaining why MDT maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 22) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$78.30
Potential Downside
14.5%
Whystock Fair Value$66.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus25 analysts
Buy
Mean target$108.00+37.9%
Range$90.00 – $121.00
Fundamentals
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable car...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$106.84B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.25
Beta
Defensive asset. Lower volatility than the S&P 500.
0.76
Div Yield
Strong income play. Yield provides a meaningful total return floor.
341.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.42%
Volume
Today's trading volume
9.07M
Recent News
Medtronic (MDT) Declines More Than Market: Some Information for Investors
Medtronic (MDT) closed the most recent trading day at $78.3, moving 2.13% from the previous trading session.
Jim Cramer Believes Competitors Might Hurt Intuitive Surgical
Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. A caller asked for Cramer’s thoughts on the company, and he said: Here’s the thing: Both J&J and Medtronic claim they’ve got competitors. And I am worried that one of those two is going to hit […]
Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones
MASI's SET pulse oximetry shows accurate, consistent readings in hospitalized newborns across all skin tones in the largest real-world study.
Medtronic plc (MDT) Receives the CE Mark for the Stealth AXiS™ Surgical System
Medtronic plc (NYSE:MDT) is one of the best medical device stocks to invest in right now. Medtronic plc (NYSE:MDT) announced on April 28 that it received the CE mark for the Stealth AXiS™ surgical system, indicated for spine and cranial procedures. Management stated that the system is a next-generation platform that amalgamates navigation, planning, and […]
Medtronic’s Stealth AXiS Europe Approval Expands Surgical Growth Story
Medtronic (NYSE:MDT) has received CE mark approval in Europe for its Stealth AXiS next generation surgical system for spine and cranial procedures. The green light follows earlier U.S. clearance and allows Medtronic to offer an integrated planning, navigation, and robotics platform to hospitals across European markets. The approval is among the early product launches under the EU Medical Device Regulation framework, expanding Medtronic's presence beyond its established cardiac and diabetes...